Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability and Aß-specific antibody response of
CAD106 in patients with mild to moderate Alzheimer's Disease.
Patients also had a 2 year follow-up to assess disease progression where no drug was
administered.